Cerevel Therapeutics Holdings, Inc.

Good morning. Welcome to the Saraville Therapeutics First Quarter 2021 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, you will have an opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded. I will now turn the call over to Matt Calistri, Vice President of Investor Relations.

Thank you. Good morning, everyone. We appreciate you joining us for our first quarter 2021 results call. On today's call, you will be hearing from Dr. Tony Coles, our chairperson and chief executive officer, Dr. Ray Sanchez, our chief medical officer, Dr. John Renger, our chief scientific officer, and Kathy Yee, our chief financial officer. We will also have a brief introduction to Abe Cisse, our new president. please refer to our press release from this morning detailing our Q1 performance as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to our financial performance, future events, and industry and market conditions, as well as forward-looking statements including the potential attributes and benefits of our product candidates and the format and timing of Cerevel's product development activities and clinical trials. We strongly encourage you to review the information that we file with the SEC regarding specific risks and uncertainties. I will now hand it over to Dr. Tony Coles, Chairperson and CEO of Cerevel, to provide an overview of our achievements and outlook.

Thanks, Matt, and good morning, everyone. Thank you for joining us for our first quarter 2021 results and business update call. Here at Ceravel, we're building the premier neuroscience company and working to do so in all respects by bringing together the people, the pipeline, and the capital we need to develop new therapies for patients in need. And we've made terrific progress in all three of these essential areas in recent months. On the people front, I'm really pleased that we have welcomed Abe Cisse to our newly created role of president. With nearly two decades of healthcare operating experience, Abe's strong track record of building commercial organizations and broad leadership capabilities is exactly what Cerevel needs as we plan for our successful transition from a clinical stage organization to a fully integrated biopharma company. As president, Abe will oversee strategy, corporate and business development, portfolio and program management, and importantly, he'll be responsible for developing our commercial infrastructure and launch capabilities. I know Abe's going to make a great contribution to Cerevel as we look ahead to introducing new therapies for patients with schizophrenia, anxiety, epilepsy, Parkinson's, and the other debilitating conditions we're focused on addressing. I'd love to turn the call over to Abe for just a moment so he can introduce himself.